Q-omics provides the consensus-scored ZNF724 profile across patient tissues and cancer cell-line models. ZNF724 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ZNF724 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, ZNF724 RNA expression shows 20,352 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, BLCA, and UVM as cancer lineages where ZNF724 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF724 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF724 survival associations across molecular data types. ZNF724 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF724 RNA expression–survival associations across cancer types. High ZNF724 expression shows unfavorable associations in MESO, LIHC, ACC and SARC, but favorable associations in UCS and KIRC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for ZNF724 RNA expression.
This table summarizes ZNF724 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF724. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF724 shows higher tumor expression in BLCA, LUAD, COAD, KIRP, UCEC and LUSC. The BLCA box plot shows higher ZNF724 RNA expression in tumor versus normal tissue (log2 FC = +1.484, t-test p < 0.001).
This table shows molecular features associated with ZNF724 in patient tissues and cancer cell lines. In patient samples, ZNF724 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF724 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
